BioSpace News Archive

TOTUM-070 is being developed particularly for individuals with untreated hypercholesterolemia, with LDL-cholesterol levels up to 190 mg/dL associated with moderate overall cardiovascular risk. It responds to an unmet medical need for this population; TOTUM-070 has high potential in the market for non-drug LDL-cholesterol products, which is estimated at 1.2 billion euros (USA + top 5 Europe) 1 ; The clinical study HEART on TOTUM-070, a Phase II

Global heart health leader implores U.S. adults to monitor their blood pressure weekly and take action if they are among the 116 million Americans in the hypertensive range

Q3 2020 net sales exceed outlook with 26% CER increase and adjusted diluted EPS grows 61% to $0.58 CER, hits high end of outlook range Full-year 2020 outlook raised to ~20% CER net sales growth and ~$2.07-2.09 CER adjusted EPS QIAGEN Virtual Deep Dive investor event planned for December 8, 2020

Cytocom, Inc., a leading biopharmaceutical company in the area of immune-modulation, today announced that its Chief Executive Officer, Michael K. Handley, will host a conference call on Wednesday, October 28, 2020, at 8:00 a.m. ET, to discuss the proposed merger with Cleveland BioLabs (CBLI) and provide a strategic vision for the combined company.

Today, AmerisourceBergen kicked off its first-ever ThinkLive Trade virtual event, a three-day online summit geared toward brand, specialty and generic manufacturers

iVeena is pleased to announce the topline results of its recently completed Phase 1/2a clinical trial, “A Randomized, Double-Masked, Trial of IVMED-80 Eyedrops for Treatment of Keratoconus.”

Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced interim data from the full patient population (n=42) in its Phase 1/2 clinical trial of avasopasem manganese

AVITA Therapeutics, Inc. (NASDAQ: RCEL, ASX:AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today it plans to release its first quarter 2021 financial results after the market closes on Wednesday, November 11, 2020.

Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, will release its financial results for the quarter ended September 30, 2020 on Tuesday, November 10, 2020, after the close of the market.

Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, today announced that it will release financial results for the quarter ended September 30, 2020 after the market close on Tuesday, November 10, 2020.